<?xml version="1.0" encoding="UTF-8"?>
<p id="Par35">Further it has immunosuppressive effects also. Hence repurposing of these drugs with the proper formulation is required to improve their safety and effectiveness for the treatment of COVID-19 [
 <xref ref-type="bibr" rid="CR154">154</xref>]. Alpha-lipoic acid, baloxavir, colchicine, interferon, lopinavir/ritonavir, favipiravir, ribavirin, ruxolitinib, among others, do not have RCTs, then no conclusions yet can be made [
 <xref ref-type="bibr" rid="CR155">155</xref>]. Ribavirin and favipiravir are RNA polymerase inhibitors and have been used alone or in combination with IFN-Î± in COVID-19 patients [
 <xref ref-type="bibr" rid="CR156">156</xref>]. Tocilizumab, ivermectin does not have RCTs yet, although they have preclinical data suggesting usefulness in COVID-19 [
 <xref ref-type="bibr" rid="CR157">157</xref>, 
 <xref ref-type="bibr" rid="CR158">158</xref>]. In any case, it should be considered that most of the drugs with biological plausibility and favourable preclinical studies ultimately did not have enough clinical benefits to allow their approval for commercialization. This indicates that medicines with biological plausibility and preclinical studies will often only cause harm and can even be fatal. Then, evidence-based decisions should be carefully assessed [
 <xref ref-type="bibr" rid="CR159">159</xref>]. LAM-002A 9 (apilimod), a drug used to treat follicular lymphoma and autoimmune diseases have proven effective against SAR-CoV-2. Yale University and AI Therapeutics firm has started a phase II trial for LAM-002A 9 to assess its effectiveness for inhibiting SARS-CoV-2 (
 <ext-link ext-link-type="uri" xlink:href="https://www.medicalnewstoday.com/articles/list-of-promising-drugs-against-covid-19-leads-to-new-treatment-trial" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.medicalnewstoday.com/articles/list-of-promising-drugs-against-covid-19-leads-to-new-treatment-trial</ext-link>).
</p>
